A Double-Blind Placebo-Controlled Trial of the Safety and Immunogenicity of a Seven Valent Pneumococcal Conjugate Vaccine in Presumed HIV-Infected Infants - Full Text View

Sponsors and Collaborators:	National Institute of Allergy and Infectious Diseases (NIAID) Lederle-Praxis Biologicals
Information provided by:	National Institute of Allergy and Infectious Diseases (NIAID)
ClinicalTrials.gov Identifier:	NCT00000829

Purpose

To assess whether HIV-infected infants who receive a heptavalent pneumococcal conjugate vaccine have more local reactions at the site of injection and systemic reactions than placebo subjects. To assess whether this vaccine is more immunogenic than placebo following the third vaccination.

Children with HIV infection are at increased risk for invasive pneumococcal infection, particularly bacteremia. A large proportion of pneumococcal disease is caused by a limited number of serotypes. The maximum number of pneumococcal serotypes that can be included in a new conjugate vaccine is felt to be limited by the amount of carrier protein. A heptavalent pneumococcal conjugate vaccine has been developed that consists of pneumococcal capsular saccharides from serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F bound to a diphtheria toxin mutant carrier protein.

Condition	Intervention	Phase
HIV Infections Pneumococcal Infections	Biological: Pneumococcal Vaccine, Polyvalent (23-valent) Biological: Pneumococcal Conjugate Vaccine, Heptavalent Biological: Placebo	Phase I

MedlinePlus related topics: AIDS

Drug Information available for: Heptavalent pneumococcal conjugate vaccine Pneumococcal Vaccines

U.S. FDA Resources

Study Type:	Interventional
Study Design:	Prevention, Randomized, Double Blind (Subject, Investigator), Parallel Assignment
Official Title:	A Double-Blind Placebo-Controlled Trial of the Safety and Immunogenicity of a Seven Valent Pneumococcal Conjugate Vaccine in Presumed HIV-Infected Infants

Further study details as provided by National Institute of Allergy and Infectious Diseases (NIAID):

Primary Outcome Measures:

Comparison of adverse reactions between PCV and placebo patients that occur within 48 hours after each injection [ Time Frame: Throughout study ] [ Designated as safety issue: Yes ]
Comparison of seroconversion rates and changes in (IgG) ELISA antibody levels between PCV and placebo patients after the primary series [ Time Frame: Throughout study ] [ Designated as safety issue: No ]

Secondary Outcome Measures:

Comparison of booster rates in serum ELISA (IgG) antibody levels just before the 4th vaccination and one month after the 4th vaccination in children receiving PCV and placebo [ Time Frame: Prior to 4th vaccination and at 1 month after 4th vaccination ] [ Designated as safety issue: No ]
Comparison of serum IgG1 and IgG2 subclass and IgA type specific seroconversion rates and changes in antibody levels in response to the primary immunization series and booster vaccination between PCV and placebo patients [ Time Frame: Throughout study ] [ Designated as safety issue: No ]
To compare the decline of serum total IgG, IgG1, IgG2, and IgA pneumococcal type specific antibody after the 3rd and after the 4th vaccination in PCV versus placebo patients [ Time Frame: At a time after the 3rd vaccination and at a time after the 4th vaccination ] [ Designated as safety issue: No ]
Modeling of the rates of seroconversion and changes in serum antibody levels in PCV patients, after the primary series and booster series, to clinical HIV staging and T-lymphocyte parameters, as well as B-lymphocyte parameters [ Time Frame: Throughout study ] [ Designated as safety issue: No ]

Enrollment:	60
Study Start Date:	November 1999
Primary Completion Date:	June 2005 (Final data collection date for primary outcome measure)

Arms	Assigned Interventions
1: Experimental Patients receiving intramuscular heptavalent pneumococcal conjugate vaccine	Biological: Pneumococcal Vaccine, Polyvalent (23-valent) Administered as an injection at 24 months of age Biological: Pneumococcal Conjugate Vaccine, Heptavalent Administered as an injection at 0, 2, 4, and 15 months of age
2: Placebo Comparator Patients receiving placebo vaccine	Biological: Pneumococcal Vaccine, Polyvalent (23-valent) Administered as an injection at 24 months of age Biological: Placebo Administered at 0, 2, 4, and 15 months of age

Detailed Description:

Children with HIV infection are at increased risk for invasive pneumococcal infection, particularly bacteremia. A large proportion of pneumococcal disease is caused by a limited number of serotypes. The maximum number of pneumococcal serotypes that can be included in a new conjugate vaccine is felt to be limited by the amount of carrier protein. A heptavalent pneumococcal conjugate vaccine has been developed that consists of pneumococcal capsular saccharides from serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F bound to a diphtheria toxin mutant carrier protein.

Infants are randomized to receive either heptavalent pneumococcal conjugate vaccine or placebo by intramuscular injection at study months 0, 2, and 4, and then at 15 months of age. Additionally, patients receive PNU-IMUNE 23 ( pneumococcal polyvalent vaccine ) at 24 months of age.

Eligibility

Ages Eligible for Study:	2 Months to 6 Months
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	No

Criteria

Inclusion Criteria

Concurrent Medication:

Allowed:

Antipyretics for rectal temperature >= 100.4 F.
Antiretroviral therapy.

Patients must have:

HIV positivity.
Birth weight at least 1800 g (3.75 lb).
Consent and compliance of parent or guardian.

NOTE:

Coenrollment in other therapeutic protocols (except ACTG 218, 230, and 279) is permitted.

Exclusion Criteria

Co-existing Condition:

Patients with the following symptoms or conditions are excluded:

Enrollment in HIV vaccine trials.
Major congenital anomalies that are incapacitating, result in immunologic abnormalities, or require major surgical procedures.
Congenital immunoglobulin deficiency, SS or SC hemoglobinopathy, or asplenia.
Hypogammaglobulinemia.

Concurrent Medication:

Excluded:

Prophylactic antipyretics.

Patients with the following prior conditions are excluded:

Acute moderate to severe intercurrent illness or fever within 72 hours prior to study entry.

Prior Medication:

Excluded:

Any prior pneumococcal vaccine.
Measles vaccine within 1 month prior to study vaccination.
Any other routine vaccine within 1 week prior to study vaccination.
Any immunosuppressant agent, including prednisone, for more than 6 weeks.

Prior Treatment:

Excluded:

Blood products within 56 days prior to study vaccination.

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00000829

Show 37 Study Locations

Sponsors and Collaborators

National Institute of Allergy and Infectious Diseases (NIAID)

Lederle-Praxis Biologicals

Investigators

Study Chair:	James King, Jr, M.D.	University of Maryland School of Medicine
Study Chair:	Sharon Nachman, M.D.	SUNY at Stony Brook

More Information

Responsible Party:	DAIDS ( Rona Siskind )
Study ID Numbers:	ACTG 292
Study First Received:	November 2, 1999
Last Updated:	September 25, 2008
ClinicalTrials.gov Identifier:	NCT00000829
Health Authority:	United States: Food and Drug Administration

Keywords provided by National Institute of Allergy and Infectious Diseases (NIAID):

Vaccines, Synthetic
Acquired Immunodeficiency Syndrome
AIDS-Related Complex
Pneumococcal Infections
Bacterial Vaccines

Study placed in the following topic categories:

Bacterial Infections
Virus Diseases
Gram-Positive Bacterial Infections
Sexually Transmitted Diseases, Viral
Streptococcal Infections
HIV Infections

Sexually Transmitted Diseases
Acquired Immunodeficiency Syndrome
AIDS-Related Complex
Retroviridae Infections
Pneumococcal Infections
Immunologic Deficiency Syndromes

Additional relevant MeSH terms:

Communicable Diseases
RNA Virus Infections
Slow Virus Diseases

Immune System Diseases
Lentivirus Infections
Infection

ClinicalTrials.gov processed this record on January 15, 2009